Best CAR-T Hospitals in China

The Beijing GoBroad Boren Hospital is equipped with innovative CAR-T Cell Therapy, employing cutting-edge cellular immunotherapy methodologies in compliance with widely accepted global protocols for patient treatment. Founded in 2014, the certified hospital is situated in Beijing, China, offering specialised cancer treatment services to both local and international clientele, with a total bed count of 200.

CAR-T treatment is a personalised treatment process where a patient’s T cells are extracted, subsequently modified so that they can identify tumors in a patient’s body. The treatment process is indicated for some blood cancers, particularly some types of lymphomas, leukemias, and multiple myeloma. Medical professionals conduct various tests to determine a patient’s prior treatments, health status, and diagnoses before initiating the CAR-T treatment program.

The GoBroad Shanghai Zhaxin Hospital and Shanghai Liquan Hospital is equipped with innovative CAR-T Cell Therapy, employing cutting-edge cellular immunotherapy methodologies in compliance with widely accepted global protocols for patient treatment. Founded in 2018, the certified hospital is situated in Shanghai, China, offering specialised cancer treatment services to both local and international clientele, with a total bed count of 300.

CAR-T treatment is a personalised treatment process where a patient’s T cells are extracted, subsequently modified so that they can identify tumors in a patient’s body. The treatment process is indicated for some blood cancers, particularly some types of lymphomas, leukemias, and multiple myeloma. Medical professionals conduct various tests to determine a patient’s prior treatments, health status, and diagnoses before initiating the CAR-T treatment program.

GoBroad Healthcare (Hematology) Guangdong Research Center employs modern cell immunotherapy technology and evidence-based cancer treatment in CAR-T Cell Therapy. Founded in 2018, the accredited hospital is located in Dongguan, China and has 200 beds and facilities for local and international patients.

CAR-T Cell Therapy involves extracting T cells and processing them to recognise a specific cancer antigen before increasing their number in the body. Depending on the cancer treatment used, patients may undergo lymphodepleting chemotherapy before receiving CAR-T cells. The multidisciplinary team assesses all aspects of the disease, past treatment regimens, organ function, and suitability for treatment.

Beijing GoBroad Hospital uses advanced cellular manufacturing techniques and immunotherapy protocols to provide CAR T-cell therapy services. Founded in 2017, this institution is based in Beijing, China, and it has adequate bed capacity, with recognition, to assist both local and foreign patients.

The CAR-T process is beneficial for some patients with blood cancers that have failed prior treatment and returned, depending on the disease type and the approved indication. In CAR-T therapy, T cells are collected, engineered to recognise cancer cells, multiplied, and then infused back after proper preparation of the cells. The cancer treatment team performs a careful assessment of the disease and health history before individualisation of treatment.